Description: Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses on the commercialization of cannabis/cannabinoids, including THC and CBD for medical and recreational applications. The company was founded in 2014 and is based in Uppsala, Sweden.
Home Page: www.klaria.com
Virdings Allé 2
Uppsala,
754 50
Sweden
Phone:
46 84 46 42 99
Officers
| Name | Title |
|---|---|
| Mr. Fredrik Hubinette | Chairman & CTO |
| Mr. Jesper Wiklund | Chief Exec. Officer |
| Mr. Scott Boyer | Chief Scientific Officer & Director |
| Mr. Hans Richter | Chief Financial Officer on Consultative |
| Ms. Susan Suchdev | Chief Operating Officer |
| Mr. Marc Willuhn Ph.D. | Head of Chemistry, Manufacturing & Control |
| Dr. Hans Olivecrona M.D., Ph.D. | Chief Medical Officer |
Exchange: ST
Country: SE : Sweden
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.4205 |
| Price-to-Sales TTM: | 8.0046 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 5 |